To include your compound in the COVID-19 Resource Center, submit it here.

As first subcutaneous anti-CD38 mAb, Darzalex Faspro secures J&J’s lead in MM, shaves hours off infusion time

FDA’s approval of a subcutaneous form of Darzalex secures J&J’s leading position in the anti-CD38 market just two months after a new entrant threatened to cut into its market share. It’s also a

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers